Drug intelligence / Profile preview

LSI-209

Development stage: Preclinical
Lead developer: LipoSeuticals
Modality: Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

LSI-209 is a small molecule reformulation being developed by LipoSeuticals for the treatment of various oncology indications. The drug is designed for intravenous (IV) administration and utilizes LipoSeuticals' proprietary liposomal delivery technology to enhance the pharmacokinetic profile and therapeutic index of a generic oncology agent. While the specific underlying active pharmaceutical ingredient has not been publicly disclosed in pipeline listings, the program is part of a broader effort to improve the delivery and efficacy of established chemotherapeutic agents through advanced lipid-based formulations.

Beyond the preview

Go deeper on LSI-209.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LSI-209.

Explore the full profile